Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1500-pRCC,Adv, Sunitinib vs MET inhib | 1 | Y | 1 Sunitinib | 148 | 33 | 13 | 6 | 2 | 1 | 0 | 07/25/2016 | 213 | 87 |
| 2 Cabozantinib | 32 | 14 | 5 | 4 | 2 | 0 | ||||||||
| 3 Crizotinib | 28 | 7 | 0 | 0 | 0 | 0 | ||||||||
| 4 Savolitinib | 30 | 10 | 1 | 0 | 0 | 0 | ||||||||
| 123 | 44 | 12 | 6 | 3 | 0 | |||||||||
| S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 1 | Y | 1 TICE BCG | 969 | 106 | 74 | 47 | 32 | 15 | 2 | 02/24/2017 | 173 | 70 | |
| 2 Tokyo-172 BCG | 106 | 75 | 47 | 32 | 16 | 4 | ||||||||
| 3 Prime + Tokyo-172 BCG | 104 | 75 | 48 | 31 | 16 | 3 | ||||||||
| 316 | 224 | 142 | 95 | 47 | 9 | |||||||||
| S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab | 1 | Y | 1 Atezolizumab | 162 | 144 | 103 | 56 | 28 | 12 | 2 | 03/13/2017 | 197 | 91 | |
| 144 | 103 | 56 | 28 | 12 | 2 | |||||||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 55 | 55 | 47 | 26 | 12 | 2 | 09/24/2018 | 222 | 90 | |
| 55 | 55 | 47 | 26 | 12 | 2 | |||||||||
| 2 | Y | 1 Standard Systemic Therapy Only | 1273 | 11 | 11 | 10 | 7 | 3 | 0 | 09/24/2018 | ||||
| 2 SST + Surgery/RT | 11 | 11 | 10 | 6 | 3 | 1 | ||||||||
| 22 | 22 | 20 | 13 | 6 | 1 | |||||||||
| Yes | A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 1 | E | Total Registrations | 5 | 2 | 1 | 1 | 1 | 0 | 11/23/2016 | 63 | 40 | |
| 5 | 2 | 1 | 1 | 1 | 0 | |||||||||
| EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) | 0 | E | Total Registrations | 47 | 33 | 25 | 16 | 7 | 2 | 09/29/2017 | 330 | 146 | ||
| 47 | 33 | 25 | 16 | 7 | 2 | |||||||||
| 1 | E | Total Registrations | 38 | 27 | 21 | 14 | 7 | 0 | 09/29/2017 | |||||
| 38 | 27 | 21 | 14 | 7 | 0 | |||||||||
| EA8171-PROS, newly diagnosed, mpMRI for pre-op stagi | 1 | E | Total Registrations | 3 | 3 | 3 | 3 | 1 | 0 | 02/11/2019 | 80 | 29 | ||
| 3 | 3 | 3 | 3 | 1 | 0 | |||||||||
| NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel | 1 | E | Total Registrations | 3 | 2 | 2 | 1 | 0 | 0 | 08/24/2017 | 220 | 104 | ||
| 3 | 2 | 2 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 3 | 2 | 2 | 1 | 0 | 0 | 08/24/2017 | |||||
| 3 | 2 | 2 | 1 | 0 | 0 | |||||||||
| NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 03/19/2019 | 7 | 3 | ||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| No | A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 0 | E | Total Registrations | 36 | 36 | 27 | 12 | 4 | 0 | 05/03/2018 | 241 | 125 | |
| 36 | 36 | 27 | 12 | 4 | 0 | |||||||||
| 1 | E | Total Registrations | 33 | 33 | 24 | 12 | 6 | 1 | 05/03/2018 | |||||
| 33 | 33 | 24 | 12 | 6 | 1 | |||||||||
| A031701-Bladder, ddGC for MIBC with DDR Tumor Alt | 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 12/17/2018 | 16 | 4 | ||
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 12/17/2018 | |||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 1 | E | Total Registrations | 5 | 5 | 3 | 1 | 1 | 0 | 08/08/2018 | 102 | 27 | ||
| 5 | 5 | 3 | 1 | 1 | 0 | |||||||||
| NRGGU006-PROS, post-RP PSA, SRT +/- ADT w/Apalutamide | 1 | E | Total Registrations | 2 | 2 | 2 | 2 | 1 | 0 | 03/22/2019 | ||||
| 2 | 2 | 2 | 2 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 1 | 03/22/2019 | |||||
| 1 | 1 | 1 | 1 | 1 | 1 | |||||||||
| R0924-Pros, NADT+WPRT vs. NADT+P&SV RT | 1 | E | Total Registrations | 92 | 20 | 3 | 1 | 0 | 0 | 11/25/2013 | 260 | 115 | ||
| 92 | 20 | 3 | 1 | 0 | 0 | |||||||||